PDIA4 inhibitors and use thereof for inhibiting ß-cell pathogenesis and treating diabetes

    公开(公告)号:AU2020397821A1

    公开(公告)日:2022-06-23

    申请号:AU2020397821

    申请日:2020-11-15

    Abstract: Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and/or reversing, returning blood glucose concentration to a normal level in a diabetic.

Patent Agency Ranking